Immunovant, Inc is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Company Profile
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
All Other Basic Organic Chemical Manufacturing (325199)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
Immunovant, Inc.
Tom Dorney, MS, MBA
Investor Relations
info@immunovant.com
Company Contact
Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018